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GH-immunoreactive cells of control adult female rat pi-
tuitaries were ovoid or pyramidal in shape, with a spherical cen-
trally located nucleus. GH cells were usually situated along sinu-
soids. In SRIH-treated rats, these cells were smaller, irregularly
shaped, with more intensely stained secretory granules. Blood
capillaries were dilated. All morphometric parameters were de-
creased in both SRIH-treated groups comparing to saline-treated
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Fig. 1. Nuclear volume (Vn ; f.Jl1l3) of GH cells in multiply and
chronically SRIH- treated females. All values are the means ± SD.
(n=5/group).
Fig. 2. Cellular volume (Vc; /un 3) of the immunoreactive GH cells.
All values are the means ± SD. (n=5/group), ap <0.05 vs the cone-
spondingcontrol; bp <0.05 v:S multiplySRIH-treated.
The neuropeptide somatostatin (SRIH) originally iso-
lated from the hypothalamus as a growth hormone (GH) re-
lease-inhibiting hormone, is widely distributed both in the cen-
tral nervous system (R e i chi i n 1983) and in the periph-
eral tissues (S h u Ike s 1994). It is well known that SRIH
inhibits GH release from somatotropes in male and female rats
(M i los e vic et al. 1998) via separate receptors in the
plasma membrane ( W e h r e n b erg et al. 1982). Hypotha-
lamic SRIH also inhibits secretion of luteinizing hormone
(L 0 v r e n et al. 1998). prolactin (PRL) (M i los e vic •
eta I. 1998) and thyrotropin-stimulating hormone (TSH)
(5 e k u lie et al. 2000; Milos e vic et al. 2000) from
the anterior pituitary in rats. In many animal tumor
models and cultured tumor cell lines, somatostatin and
somatostatin analogs inhibit tumor growth (R e ubi and
L a iss u e 1995), probably, because the highest incidence of
somatostatin receptors was observed in neuroendocrine tumors
(R e ubi 1997).
This study was designed to evaluate the effects of multiple
and chronical sub cutaneous (s.c.) treatment with SRIH on the
stereology and morphology of somatotropes in pituitary glands of
the female rats.
The study was performed using adult female Wistar rats
(210-230 g). The rats were divided into four experimental
groups of five animals per group. The first group received
two 100 fig/kg b.w. SRIH doses per day (R e b u f fat et al.
1984). for five consecutive days (75-79th day of life; multiple
treatment). Females of the second group received two
20 Jlg/I00 g b.w. SRIH doses per day, from the 23rd day till
the 71st day of life (chronical treatment). The somatostatin
used was cyclic somatostatin-14 (Bachern, PSOMIO, USA).
The third and the fourth group were the corresponding con-
trols. Females of these groups were treated multiply or chroni-
cally with saline only. All animals were sacrificed under deep
anesthesia by decapitation during 12 h after the last injection.
Pituitary glands were excised, fixed in Bouin's solution and
embedded in paraffin. Pituitary GH cells were immunocyto-
chemically localized by the peroxidase-antiperoxidase-complex
(PAP) method of S t ern b erg e r et al. (1970). Measu-
rements were performed on the widest portion of the pituitary
gland. Immunopositive GH cells were analyzed by the M42 test
system after Wei bel (1979). For the calculations of the cell
and nuclear volumes the formula of Wei bel (1979) was
used. Morphometric data obtained from each group were
averaged, and the standard deviation of the mean was calcu-
lated. A one-way analysis of variance (AN OVA), followed by
the multiple range test of Duncan was used for statistical com-
parisons between the groups. A probability value of 5% or less
was considered statistically significant.
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rats (Figs. 1-3). The nuclear volume of GH cells was insignifi-
cantly decreased (p>o.05; by 15%) after both multiple and chroni-
cal SRIH-14 treatment in comparison with the corresponding
controls (Fig. 1). 111e cellular volume of GH cells was significantly
decreased (p<0.05) in both multiply and chronically treated ani-
mals, by 39% and 56%, respectively (Fig 2), in relation to the
corresponding controls. After chronical SRIH-14 treatment, the
GH cells volume was lower by 22% (p<0.05) than after multiple
SRIH-14 treatment. The volume density of GH cells in both
SRIH-treated groups was decreased by 29% in the first and by
45% in the second group (p<0.05) in relation to the correspond-
ing controls (Fig. 3). The volume density of GH cells in chroni-
cally treated rats was significantly decreased (p<o.05) by 28% in
comparison with multiply SRIH-treated rats (Fig. 3).
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previous observations that SRIH-14 and SRIH-28 given in-
tracerebroventricularly to male and female rats led to a decrease
in the number of GH cells, accompanied by a reduction in both
their cellular and nuclear volumes in comparison with the controls
(M i los e vic et aL 1998, 2000). The inhibition of GH re-
lease by SRIH involves a change in the distribution of microfila-
ments rather than microtubules (S him a d a et aL 1990).
These authors found microfilament bundles running parallel to
the plasmalemma in the space between the granules after injec-
tion of SRIH.
In conclusion, systemic application of SRIH-14 by s.c.
route induced marked changes in immunocytochemical and
. morphometric characteristics of pituitary GH cells. The vol-
ume and volume density of GH cells were significantly reduced
after multiple and chronical SRIH-14 treatment. However, in
chronically treated females a more markedly expressed inhibi-
tory effects of SRIH-14 on GH cells were found than in multi-
ply treated animals.
Fig. 3. Relative volume density (Vv; %) of GH cells expressed as
percentages of total gland tissue. All values are the means ± SD.
(n=5/group), ap <O.05 ~.:s corresponding control; hp<O.05 v.s multiply
SRIH-treated.
The results of the present study demonstrate that multi-
ply or chronically applied SRIH-14 expressed an inhibitory
influence on GH cells morphology in female rats. Morphome-
tric and quantitative changes of GH pituitary cells were more
obvious in animals chronically treated with SRIH-14 than after
multiple SRIH-14 treatment. This data is in accordance with our
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